Kane Biotech Announces Issuance of Restricted Share Units
WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company pursuant to the third amended and restated performance and restricted share unit plan of the Company dated May 22, 2024 (the “PRSU Plan”). Each RSU is exercisable into one common share of the Company (a “Share”). The RSUs will vest at different times, but none will vest earlier than 12 months from the date of grant.
Related news for (KNBIF)
- Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
- Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
- Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
- Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
- Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel